GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET

ConditionChronic Endometritis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age20-40

SponsorGuoxia Yang

About this trial

Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,

Eligibility criteria

Qualifiers

Aged 20-40 years; confirmed persistent chronic endometritis (PCE) via hysteroscopy plus CD138 immunohistochemistry, defined as positive endometrial pathology after two-course antibiotic treatment for CE.

Frozen-thawed embryo transfer (FET) with available transferable cleavage-stage or blastocyst embryos from IVF/ICSI cycles.

No acute pelvic infection at enrollment; ≥1 month elapsed after completion of last antibiotic therapy for endometritis.

Normal uterine cavity except for inflammatory changes of PCE; no severe uterine malformation or severe intrauterine adhesion requiring surgical intervention.

Disqualifiers

History of pelvic tuberculosis, intrauterine adhesions, submucous uterine myoma or endometrial polyp before FET

Uncontrolled systemic endocrine disorders, autoimmune diseases (APS, SLE), severe hepatic/renal/cardiopulmonary dysfunction.

Known allergy to GnRH agonist for down-regulation regimen; prior long-acting GnRH-a intolerance.

Recent use of immunosuppressant, long-term glucocorticoid or drugs interfering endometrial development within 3 months before enrollment.

Trial design

Treatments tested in this trial

Conventional estrogen-progesterone artificial cycle for endometrial preparation
GnRH agonist plus estrogen-progesterone for endometrial preparation

Treatment groups

150 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Guoxia Yang

Lead sponsor

First Affiliated Hospital, Sun Yat-Sen University

Sponsor institution

Source ClinicalTrials.gov